- •CONTENTS
- •PREFACE
- •ABBREVIATIONS
- •GENERAL AND COLORECTAL
- •CASE 1:
- •ANSWER 1
- •CASE 2:
- •ANSWER 2
- •CASE 3:
- •ANSWER 3
- •CASE 4:
- •ANSWER 4
- •CASE 5:
- •ANSWER 5
- •CASE 6:
- •ANSWER 6
- •CASE 7:
- •ANSWER 7
- •CASE 8:
- •ANSWER 8
- •CASE 9:
- •ANSWER 9
- •CASE 10:
- •ANSWER 10
- •CASE 11:
- •ANSWER 11
- •CASE 12:
- •ANSWER 12
- •CASE 13:
- •ANSWER 13
- •CASE 14:
- •ANSWER 14
- •CASE 15:
- •ANSWER 15
- •CASE 16:
- •ANSWER 16
- •CASE 17:
- •ANSWER 17
- •CASE 18:
- •ANSWER 18
- •CASE 19:
- •ANSWER 19
- •CASE 20:
- •ANSWER 20
- •UPPER GASTROINTESTINAL
- •CASE 21:
- •ANSWER 21
- •CASE 22:
- •ANSWER 22
- •CASE 23:
- •ANSWER 23
- •CASE 24:
- •ANSWER 24
- •CASE 25:
- •ANSWER 25
- •CASE 26:
- •ANSWER 26
- •CASE 27:
- •ANSWER 27
- •CASE 28:
- •ANSWER 28
- •CASE 29:
- •ANSWER 29
- •CASE 30:
- •ANSWER 30
- •CASE 31:
- •ANSWER 31
- •CASE 32:
- •ANSWER 32
- •CASE 33:
- •ANSWER 33
- •CASE 34:
- •ANSWER 34
- •CASE 35:
- •ANSWER 35
- •CASE 36:
- •ANSWER 36
- •BREAST AND ENDOCRINE
- •CASE 37:
- •ANSWER 37
- •CASE 38:
- •ANSWER 38
- •CASE 39:
- •ANSWER 39
- •CASE 40:
- •ANSWER 40
- •CASE 41:
- •VASCULAR
- •CASE 42:
- •ANSWER 42
- •CASE 43:
- •ANSWER 43
- •CASE 44:
- •ANSWER 44
- •CASE 45:
- •ANSWER 45
- •CASE 46:
- •ANSWER 46
- •CASE 47:
- •ANSWER 47
- •CASE 48:
- •ANSWER 48
- •CASE 49:
- •ANSWER 49
- •CASE 50:
- •ANSWER 50
- •CASE 51:
- •ANSWER 51
- •CASE 52:
- •ANSWER 52
- •CASE 53:
- •ANSWER 53
- •CASE 54:
- •ANSWER 54
- •CASE 55:
- •ANSWER 55
- •CASE 56:
- •ANSWER 56
- •UROLOGY
- •CASE 57:
- •ANSWER 57
- •CASE 58:
- •ANSWER 58
- •CASE 59:
- •ANSWER 59
- •CASE 60:
- •ANSWER 60
- •CASE 61:
- •ANSWER 61
- •CASE 62:
- •ANSWER 62
- •CASE 63:
- •ANSWER 63
- •CASE 64:
- •ANSWER 64
- •ORTHOPAEDIC
- •CASE 65:
- •ANSWER 65
- •CASE 66:
- •ANSWER 66
- •CASE 67:
- •ANSWER 67
- •CASE 68:
- •ANSWER 68
- •CASE 69:
- •Questions
- •ANSWER 69
- •CASE 70:
- •ANSWER 70
- •CASE 71:
- •ANSWER 71
- •CASE 72:
- •ANSWER 72
- •CASE 73:
- •ANSWER 73
- •CASE 74:
- •ANSWER 74
- •CASE 75:
- •ANSWER 75
- •CASE 76:
- •ANSWER 76
- •CASE 77:
- •ANSWER 77
- •CASE 78:
- •ANSWER 78
- •CASE 79:
- •ANSWER 79
- •CASE 80:
- •ANSWER 80
- •CASE 81:
- •ANSWER 81
- •EAR, NOSE AND THROAT
- •CASE 82:
- •ANSWER 82
- •CASE 83:
- •ANSWER 83
- •CASE 84:
- •ANSWER 84
- •CASE 85:
- •ANSWER 85
- •NEUROSuRGERY
- •CASE 86:
- •ANSWER 86
- •CASE 87:
- •ANSWER 87
- •CASE 88:
- •ANSWER 88
- •CASE 89:
- •ANSWER 89
- •ANAESTHESIA
- •CASE 90:
- •ANSWER 90
- •CASE 91:
- •ANSWER 91
- •CASE 92:
- •ANSWER 92
- •CASE 93:
- •ANSWER 93
- •CASE 94:
- •ANSWER 94
- •POSTOPERATIVE COMPLICATIONS
- •CASE 95:
- •ANSWER 95
- •CASE 96:
- •ANSWER 96
- •CASE 97:
- •ANSWER 97
- •CASE 98:
- •ANSWER 98
- •CASE 99:
- •ANSWER 99
- •CASE 100:
- •ANSWER 100
100 Cases in Surgery
ANSWER 35
The normal spleen is approximately 11 cm in length and is not normally palpable. The spleen classically enlarges towards the right iliac fossa, has a palpable notch and is dull to percussion. The superior border of the spleen cannot be reached on palpation, differentiating it from renal masses. The spleen is responsible for the synthesis of immunoglobulins and the clearance of micro-organisms, antigens and abnormal red blood cells from the circulation. Enlargement of the spleen is usually due to overactivity of its normal functions.
!Causes of enlargement of the spleen
•Infective:
•Acute: septicaemia, infective endocarditis, typhoid, infective mononucleosis
•Chronic: tuberculosis, hepatitis, brucellosis, hiv
•Parasitic: malaria, kala-azar (leishmaniasis), schistosomiasis
•Inflammatory:
•Rheumatoid arthritis
•Sarcoidosis
•Systemic lupus erythematosus
•Haematological:
•leukaemia
•lymphoma
•haemolysis (thalassaemia, sickle cell disease)
•myeloproliferative disorders
•Portal hypertension
•Miscellaneous:
•Storage disorders
•amyloid
•Causes of massive splenomegaly:
•Myelofibrosis
•Chronic myeloid leukaemia
•Chronic malaria
•Kala-azar
The blood film would suggest this patient has myelofibrosis. There is progressive scarring of the bone marrow leading to blood formation in extra-medullary sites, such as the liver and spleen, causing enlargement of these organs. The cause is unknown. The disorder usually develops slowly, in people over 50 years of age. It leads to progressive bone-marrow failure with severe anaemia. The diagnosis is made on examination of the blood films, showing teardrop-shaped red blood cells, and on bone-marrow biopsy.
There is no specific treatment for primary myelofibrosis. Blood transfusions and erythropoietin are given to correct the anaemia. A splenectomy may help if the enlarged size of the spleen causes thrombocytopenia. Splenectomy can be performed through a subcostal incision or laparoscopically. The patient should be crossmatched prior to the procedure, and platelets ordered if the platelet count is low. Those patients who undergo splenectomy have a lifetime risk of septicaemia and should receive immunizations against Pneumococcus, Haemophilus and Meningococcus.
KEY POINTS
the characteristics of the spleen on clinical examination are:
•the superior border cannot be felt
•the medial border is notched
•it is dull to percussion
•it enlarges towards the right iliac fossa
80
Upper Gastrointestinal
CASE 36: FinDing at gaStroSCopy
history
A GP has referred a 56-year-old man for an oesophagogastroduodenoscopy. The patient presented to the GP 2 months previously with epigastric discomfort and bloating. He was prescribed a proton pump inhibitor, which failed to improve his symptoms. He has no history of gastro-oesophageal reflux or gallstones and is not on any other regular medication. He smokes 20 cigarettes a day. The GP also sent some blood tests, shown below.
INVESTIGATIONS
|
|
Normal |
haemoglobin |
9.0 g/dl |
11.5–16.0 g/dl |
mean cell volume |
69 fl |
76–96 fl |
White cell count |
10.2 × 109/l |
4.0–11.0 × 109/l |
platelets |
252 × 109/l |
150–400 × 109/l |
Sodium |
137 mmol/l |
135–145 mmol/l |
potassium |
3.9 mmol/l |
3.5–5.0 mmol/l |
urea |
5.0 mmol/l |
2.5–6.7 mmol/l |
Creatinine |
59 μmol/l |
44–80 μmol/l |
amylase |
78 iu/dl |
0–100 iu/dl |
aSt |
30 iu/dl |
5–35 iu/l |
ggt |
23 iu/dl |
11–51 iu/l |
albumin |
45 g/l |
35–50 g/l |
bilirubin |
12 mmol/l |
3–17 mmol/l |
glucose |
5.0 mmol/l |
3.5–5.5 mmol/l |
the endoscopy results are shown in Figure 36.1.
Figure 36.1 Finding on endoscopy.
Questions
•What does the endoscopy show?
•What do the blood tests reveal?
•What are the risk factors for this diagnosis?
•How should the patient be staged?
•What are the treatment options?
81
100 Cases in Surgery
ANSWER 36
The gastroscopy has revealed a gastric tumour. The blood tests show a microcytic anaemia, as a result of chronic blood loss from the tumour. This patient will have had multiple biopsies taken at endoscopy and will now require staging. Gastric carcinoma is the second commonest cause of cancer worldwide. The majority are adenocarcinomas, with the remainder made up of lymphomas, stromal or neuroendocrine tumours. The highest incidence is in Eastern Asia, with a falling incidence in Western Europe. Diet and H. pylori infection are thought to be the two most important environmental factors in the development of gastric cancer. Diets rich in pickled vegetables, salted fish and smoked meats are thought to predispose to gastric cancer. These factors contribute to a premature atrophic gastritis, a precursor state to malignant transformation. Fruits and vegetables are protective.
!Risk factors for gastric malignancy
•vitamin C deficiency
•Helicobacter pylori infection
•hypogammaglobulinaemia
•pernicious anaemia
•post-gastrectomy
Gastric cancer typically presents late and is associated with a poor prognosis. Clinical examination may reveal supraclavicular lymphadenopathy or hepatic enlargement, indicative of metastatic disease. Endoscopic ultrasound allows assessment of tumour depth and nodal involvement. CT also allows nodal spread and the extent of metastatic disease to be assessed (Figure 36.2).
Figure 36.2 Computerized tomography showing gastric wall thickening (arrow) as a result of gastric cancer. no liver metastases are seen.
Laparoscopy is useful to identify any peritoneal seedlings that are not detected on conventional imaging.
Antral tumours may be suitable for a sub-total gastrectomy. If the tumour is less than 5 cm from the gastro-oesophageal junction, the patient will require a total gastrectomy. For superficial tumours less than 1 cm in size, some centres are now carrying out endoscopic mucosal
82
Upper Gastrointestinal
resection. Perioperative chemotherapy (before and after surgery) improves survival for those patients suitable for surgical resection.
KEY POINTS
•gastric cancer often presents late with metastatic disease.
•Surgical resection is not possible in the majority of patients.
83
This page intentionally left blank